[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Heart and Diabetes Center North-Rhine Westfalia\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":126},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,75,100],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100589185","ct-prediction-for-transcatheter-tricuspid-interventions-100589185",false,"NCT06951126","CT Prediction for Transcatheter Tricuspid Interventions","CESAR-TR","Inclusion Criteria:\n\n* the patient underwent full cycle cardiac computed tomography for analysis of valvular heart disease\n* a transcatheter tricuspid valve intervention is performed\n* the patient is 18 years or older\n\nExclusion Criteria:\n\n* none","ALL","18 Years",{"count":19,"type":20},500,"ESTIMATED","OBSERVATIONAL","The aim of this study is to enhance the predictability of therapeutic success in transcatheter tricuspid valve intervention (TTVI) for patients with severe tricuspid regurgitation (TR). This will be achieved through automated analyses of pre-interventional computed tomography (CT) scans.\n\nSevere tricuspid regurgitation is associated with poor patient outcomes. In advanced stages, pharmacological therapy becomes ineffective, and surgical intervention carries a high mortality risk. Given this clinical challenge, catheter-based treatment of the tricuspid valve has become a focal point of research.\n\nOne well-established treatment strategy is percutaneous tricuspid valve intervention, which aims to reduce regurgitation either through annuloplasty, leaflet-based edge-to-edge repair or valve replacement. This approach has been shown to significantly decrease the severity of regurgitation, leading to a dramatic reduction in symptom burden and a marked improvement in quality of life.\n\nHowever, predicting which patients will benefit most from TTVI and determining the optimal technique for each individual remain largely unresolved challenges.\n\nArtificial intelligence (AI)-powered software, such as heart.ai by LARALAB (Munich), enables automated measurement of anatomical structures captured via CT imaging. This technology already allows for rapid and precise assessment of cardiac chambers and the tricuspid annulus throughout the entire cardiac cycle, facilitating a comprehensive three-dimensional evaluation of right heart anatomy.\n\nTo refine patient selection and optimize procedural strategies for TR treatment, the researcher work a multi-center collaboration to analyze treatment outcomes and patient response to specific therapeutic approaches.",[24,25],"Tricuspid Regurgitation","Computed Tomography",[27,28,29,30,31],"transcatheter tricuspid valve intervention","TTVI","TR","MSCT","Tricuspid regurgitation","RECRUITING","2025-04-22",{"date":35,"type":36},"2025-04-30","ACTUAL",{"date":38,"type":36},"2023-07-19",{"date":40,"type":20},"2030-06-01",{"name":42,"class":43},"Heart and Diabetes Center North-Rhine Westfalia","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":44},"100558850","preventive-catheter-ablation-for-ventricular-arrhythmias-in-patients-with-end-stage-heart-failure-100558850","NCT06556485","Preventive Catheter Ablation for Ventricular arrhythmiaS in Patients With End-sTage Heart faiLure","Preventive Catheter Ablation for Ventricular arrhythmiaS in Patients With End-sTage Heart faiLure rEfferred for Heart Transplantation eValuaTion (CASTLE-VT)","CASTLE-VT","Inclusion Criteria:\n\n1. Ischemic cardiomyopathy with left ventricular ejection fraction ≤ 35% (measured in the last 6 weeks prior to enrollment)\n2. Eligible for heart transplantation due to end-stage heart failure\n3. NYHA class ≥ III\n4. Impaired functional capacity or inability to exercise\n5. Indication for ICD therapy due to primary prevention\n6. Implanted ICD or ICD implantation within 3 months after randomization\n7. The patient is willing and able to comply with the protocol and has provided written informed consent\n8. Age ≥ 18 years\n\nExclusion Criteria:\n\n1. Previous catheter ablation for ventricular arrhythmias\n2. Previous appropriate ICD-therapy for ventricular arrhythmias\n3. Acute coronary syndrome, cardiac surgery, angioplasty, or cerebrovascular accident within 4 weeks prior to enrollment\n4. Untreated hypothyroidism or hyperthyroidism\n5. Woman currently pregnant, breastfeeding, or not using reliable contraceptive measures during fertility age\n6. Mental or physical inability to participate in the study\n7. Listed as \"high urgent\" for heart transplantation\n8. Cardiac assist device implanted\n9. Planned cardiovascular intervention\n10. Life expectancy ≤ 12 month\n11. Uncontrolled hypertension\n12. Requirement for dialysis due to end-stage renal failure","99 Years",{"count":55,"type":20},160,"INTERVENTIONAL",[58],"NA","CASTLE-VT is a randomized evaluation of prophylactic ablative treatment of arrhythmogenic ventricular scar in patients referred for HTx evaluation and diagnosed with ICM. Ablation will be performed with the use of a substrate-based approach in which the myocardial scar is mapped and ablated while the heart remains predominantly in sinus rhythm. The primary end point is the composite of all-cause mortality, worsening of HF requiring prioritized transplantation or LVAD implantation. The main secondary study end points are all-cause mortality, cardiovascular mortality, incidence of implantable cardioverter-defibrillator (ICD) therapy, hospitalizations, Quality of life, time to first ICD therapy, number of device-detected ventricular tachycardia\u002Fventricular fibrillation episodes, LV function, and exercise tolerance. CASTLE-VT will randomize 160 patients with a follow up period of 2 years.",[61,62,63,64,65,66],"Heart Failure","Arrhythmia, Ventricular","Cardiomyopathy Ischemic","Catheter Ablation","Heart Transplantation","Left Ventricular Assist Device","2024-12-01",{"date":69,"type":36},"2024-12-04",{"date":71,"type":36},"2024-09-13",{"date":73,"type":20},"2027-01-01",{"name":42,"class":43},{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":56,"phases":85,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":44},"100570391","impact-of-enhanced-information-on-subjective-information-level-and-proms-in-patients-with-aortic-stenosis-100570391","NCT06706635","Impact of Enhanced Information on Subjective Information Level and PROMs in Patients with Aortic Stenosis","Impact of Enhanced Information Provision by Using a Mobile App on Subjective Information Level As the Basis for Shared-decision Making and Patient-reported Outcome Measures (PROMs) in Patients with Aortic Stenosis","TAVI-SDM-APP","Inclusion Criteria:\n\n* severe aortic valve stenosis\n* planned aortic valve replacement (TAVI)\n* Patient is willing and able to complete the surveys in German language\n* Written informed consent by the trial subject\n\nExclusion Criteria:\n\n\\- Language barrier",{"count":84,"type":20},250,[58],"The aim of this trial is to evaluate if an enhanced information by using a mobile App can increase subjective information level in patients with severe aortic stenosis and may therefore improve patient-reported outcomes.",[88],"Aortic Stenosis Disease",[90,91],"aortic stenosis","mobile app","2024-11-22",{"date":94,"type":36},"2024-11-26",{"date":96,"type":36},"2024-08-21",{"date":98,"type":20},"2025-12",{"name":42,"class":43},{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":16,"minAge":108,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":111,"conditions":112,"keywords":115,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":120,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":44},"100430239","correlation-of-ffr-and-ifr-with-cardiac-pet-perfusion-in-patients-with-severe-aortic-valve-stenosis-100430239","NCT04882488","Correlation of FFR and iFR With Cardiac PET Perfusion in Patients With Severe Aortic Valve Stenosis","Correlation of FFR and iFR With Cardiac PET Perfusion (at Rest and Under Adenosine) in the Evaluation of Intermediate Coronary Stenoses in Patients With Severe Aortic Valve Stenosis","TAVI PET","Inclusion Criteria:\n\n* patients with severe aortic Stenosis eligible for transcatheter aortic stenosis\n* left ventricular ejection fraction \\> 55%\n* no intolerance of Adenosin\n* no history of bradycardia, atrioventricular Blockade\n* intermediate coronary Stenosis with FFR\\> 0.8\n* Age \\>65\n\nExclusion Criteria:\n\n* intolerance of Adenosin\n* left ventricular ejection fraction \\\u003C 55%","65 Years",{"count":110,"type":20},20,"Aortic valve stenosis (AS) affects 2-7% of persons \\> 65 years, symptoms include: angina and dyspnea, dizziness and syncope. Coincidence of coronary artery disease (CAD), also presenting with angina and dyspnea, in patients with AS between 40 - 65% . Angina in AS caused by significant reduction of coronary flow reserve (CFR). CFR is the ratio of maximal flow increase in the coronary vessel bed during maximal hyperaemia (medically or exercise induced). FFR (fractional flow reserve) use in patients with AS potentially invalid due to dysfunctional CFR leading to potential undertreatment of CAD in these patients.CFR disturbance in AS mainly due to myocardial overload causing concentric hypertrophy, increased oxygen consumption and neurohormonal activation leading to increased vascular resistance. Current studies are investigating the validity of FFR and iFR in AS patients. Recent data demonstrate very good correlation between FFR and iFR derived values to PET myocardial perfusion imaging values in patients with no evidence of AS. Our study aims to investigate the diagnostic performance of FFR and iFR in intermediate-grade coronary stenosis in patients with severe aortic valve disease and correlate FFR- and iFR derived values with those extracted from PET-perfusion Imaging.",[113,114],"Aortic Valve Stenosis","Coronary Artery Disease",[116,117,118,119],"Aortic valve stenosis","PET-CT","coronary artery disease","FFR",{"date":94,"type":36},{"date":122,"type":36},"2021-06-01",{"date":124,"type":20},"2025-09-30",{"name":42,"class":43},""]